Next Article in Journal
Improved Beam Angle Arrangement in Intensity Modulated Proton Therapy Treatment Planning for Localized Prostate Cancer
Next Article in Special Issue
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
Previous Article in Journal
Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets
Article Menu

Export Article

Open AccessReview
Cancers 2015, 7(2), 556-573; doi:10.3390/cancers7020556

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance

1
Center for Oncological Research Antwerp, University of Antwerp, Universiteitsplein 1, Wilrijk 2610, Belgium
2
Molecular Pathology Unit, Pathology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650, Belgium
3
Department of Oncology, Clínica Universidad de Navarra, Pamplona 31008, Spain
4
Thoracic Oncology Program, Memorial Cancer Institute, Memorial Health Care System, Pembroke Pines, FL 33024, USA
5
Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy viale Alfieri 36, Livorno 57100, Italy
6
Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650, Belgium
*
Author to whom correspondence should be addressed.
Academic Editor: William Cho
Received: 5 January 2015 / Revised: 19 February 2015 / Accepted: 5 March 2015 / Published: 25 March 2015
(This article belongs to the Special Issue Non-Small Cell Lung Cancer Therapies)
View Full-Text   |   Download PDF [662 KB, uploaded 25 March 2015]   |  

Abstract

In the last decade, the tyrosine kinase receptor cMET, together with its ligand hepatocyte growth factor (HGF), has become a target in non-small cell lung cancer (NSCLC). Signalization via cMET stimulates several oncological processes amongst which are cell motility, invasion and metastasis. It also confers resistance against several currently used targeted therapies, e.g., epidermal growth factor receptor (EGFR) inhibitors. In this review, we will discuss the basic structure of cMET and the most important signaling pathways. We will also look into aberrations in the signaling and the effects thereof in cancer growth, with the focus on NSCLC. Finally, we will discuss the role of cMET as resistance mechanism. View Full-Text
Keywords: cMET, NSCLC, targeted therapies cMET, NSCLC, targeted therapies
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Van Der Steen, N.; Pauwels, P.; Gil-Bazo, I.; Castañon, E.; Raez, L.; Cappuzzo, F.; Rolfo, C. cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. Cancers 2015, 7, 556-573.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top